Imaging of malignant pleural mesothelioma: it is possible a screening or early diagnosis program?—a systematic review about the use of screening programs in a population of asbestos exposed workers

Falaschi, Fabio; Romei, Chiara; Fiorini, Sara; Lucchi, Marco

doi:10.21037/jtd.2017.12.57

Cited by 12 publications

(8 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Its median survival rate is around 12 months. Recent studies reported that, the incidence of disease has increased [1][2][3][4][5]. MPM is generally detected in advanced stages after the long latency period.…”

Section: Discussionmentioning

confidence: 99%

How can we use positron emission tomography/ computed tomography more accurately for characterization of asbestos-related pleural thickening?

et al. 2021

View full text Add to dashboard Cite

IntroductionThere is no consensus about standardized uptake value maximum (SUVmax) cut-off value to characterize pleural thickening worldwide. Sometimes, this causes unnecessary invasive diagnostic procedures. Our first aim is to determine a cut-off value for SUVmax. Secondly, we try to answer this question “If we use this cut-off value together with morphological parameters, can we differentiate benign thickening from Malignant pleural mesothelioma (MPM) more accurately”.Material and methodsThirty-seven patients with performed 2-deoxy-2-[18F]-fluoro-D-glucose ([18F]FDG-PET/CT) before pleural biopsy included the study. All of patients had histopathologically proven primary pleural disease. Their [18F]FDG-PET/CT imaging reports were re-assessed. If patient’s SUVmax or size of the thickening was not mentioned in report, we calculated them with their [18F]FDG-PET/CT.ResultsAge, pleural effusion, size, and SUVmax were found a relationship with MPM. We found the size>14 mm, and SUVmax>4.0 as cut-off values for MPM. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for size>14 mm were found as 86.4%, 85.2%, 82.6%, 88.5%, respectively. For SUVmax>4.0; sensitivity, specificity, PPV, NPV were 90.9%, 87.0%, 85.1%, 92.2%, respectively.ConclusionsIf a patient has SUVmax>4.0 and/or size>14 mm, the risk of MPM is high. These patients should be undergone biopsy. If patient’s SUVmax<4.0, size<14 mm and does not have pleural effusion, he/she has low risk for MPM. These patients can be undergone to the follow-up. If a patient's SUVmax<4, Size<14, and has pleural effusion MPM risk is approximately 4%. These patients can be undergone biopsy/cytology/follow-up. Novel studies are needed for these patients.

show abstract

Section: Discussionmentioning

confidence: 99%

How can we use positron emission tomography/ computed tomography more accurately for characterization of asbestos-related pleural thickening?

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Interestingly, this appearance on ultrasonography was similar to that of human mesothelioma of the tunica vaginalis testis, where the hydrocele showed a good contrast against the small nodules attached to the surface of the tunica vaginalis (11). In contrast-enhanced volumetric CT, which is one of the gold standard examinations for mesothelioma in humans, the characteristic findings for malignant pleural diseases including mesothelioma were mainly parietal and nodular pleural thickening (12). In one report of canine thoracic mesothelioma, a characteristic CT finding of parietal subpleural thickening was described (6).…”

Section: Discussionmentioning

confidence: 99%

Pericardial Mesothelioma in a Dog: The Feasibility of Ultrasonography in Monitoring Tumor Progression

et al. 2019

View full text Add to dashboard Cite

A 6-year-old neutered male Yorkshire Terrier presented with recurrent pericardial effusion. Although clinical examinations including computed tomography were inconclusive, an exploratory thoracotomy revealed multiple small nodules and plaques on the inner surface of the pericardial sac (Day 1). A subtotal pericardiectomy was performed to prevent cardiac tamponade due to the increasing pericardial effusion, and the resected section of the pericardium was histopathologically diagnosed with mesothelioma. After surgery, chemotherapy with intrathoracic carboplatin was commenced. During the course of the treatment, a detailed follow-up ultrasonographic scan was performed to detect early lesions disseminated on the pleura, originating from the primary pericardial mesothelioma. On Day 101, the minute pleural nodules, which were disseminated lesions as predicted, were successfully imaged by ultrasonography. As the clinical stage advanced, the nodules were observed to gradually increase in size and number, implying tumor progression. These observations highlight the feasibility of ultrasonography in detecting minute disseminated lesions at an early stage, monitoring tumor progression, and thereby, predicting the prognosis of canine pericardial mesothelioma.

show abstract

“…21,22 Computerized tomography, however, has not proven to be useful for mesothelioma screening in high-risk asbestos-exposed populations. 23 Volumetric analysis as well as other linear approaches for estimating the bulk of disease demonstrated correlations with the prognosis of patients with the disease. 24 Metabolic imaging with 18 F-labeled fluorodeoxyglucosepositron emission tomography-CT is also crucial in defining the extent of disease, especially in individuals who are being considered for resection.…”

Section: Radiology Technologymentioning

confidence: 99%

Section: Radiology Technologymentioning

confidence: 99%

New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options

Tsao

Pass

Rimner

et al. 2022

JCO

View full text Add to dashboard Cite

Malignant pleural mesothelioma (MPM) is a rare malignancy with few treatment options. Recent advances have led to US Food and Drug Administration approvals and changes in the standard of care with a novel biomedical device approved for use with platinum-pemetrexed, and also for immunotherapy agents to be included as a frontline treatment option in unresectable disease. Although predictive biomarkers for systemic therapy are not currently in use in clinical practice, it is essential to correctly identify the MPM histology to determine an optimal treatment plan. Patients with nonepithelioid MPM may have a greater magnitude of benefit to dual immunotherapy checkpoint inhibitors and this regimen should be preferred in the frontline setting for these patients. However, all patients with MPM can derive benefit from immunotherapy treatments, and these agents should ultimately be used at some point during their treatment journey. There are ongoing studies in the frontline unresectable setting that may further define the frontline therapy space, but a critical area of research will need to focus on the immunotherapy refractory population. This review article will describe the new developments in the areas of biology with genomics and chromothripsis, and also focus on updates in treatment strategies in radiology, surgery, radiation, and medical oncology with cellular therapies. These recent innovations are generating momentum to find better therapies for this disease.

show abstract

Imaging of malignant pleural mesothelioma: it is possible a screening or early diagnosis program?—a systematic review about the use of screening programs in a population of asbestos exposed workers

Cited by 12 publications

References 43 publications

How can we use positron emission tomography/ computed tomography more accurately for characterization of asbestos-related pleural thickening?

How can we use positron emission tomography/ computed tomography more accurately for characterization of asbestos-related pleural thickening?

Pericardial Mesothelioma in a Dog: The Feasibility of Ultrasonography in Monitoring Tumor Progression

New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options

Contact Info

Product

Resources

About